#United States #San Diego #Sanguine Biosciences #oncology clinics #biospecimens

Sanguine Biosciences Expands Oncology Sample Services

In a significant move aimed at advancing cancer research, Sanguine Biosciences, a prominent provider in the field of human biospecimens, has expanded its offerings by partnering with several oncology clinics across the United States. This expansion allows Sanguine to provide a diverse array of high-quality biospecimens, particularly treatment-naive samples, which will play a crucial role in the discovery and development of innovative cancer therapies.

Enhancing Access to High-Quality Biospecimens

The new collaborations ensure that researchers now have access to a widened inventory of biospecimens, which encompasses various biological materials such as blood, plasma, serum, and peripheral blood mononuclear cells (PBMCs). These samples are collected using minimally invasive techniques, thereby mitigating any discomfort for donors and enhancing the speed at which studies can commence.

One of the standout features of the newly available treatment-naive samples is their potential to yield critical insights into disease biology at its earliest stages. Researchers will benefit from studying these samples to identify immune responses, discover biomarkers for diagnostic developments, and find new therapeutic targets that exist prior to any medical intervention.

Integrated Technology for Data Management

Sanguine utilizes an advanced technology platform that simplifies the management of donor data. By securely importing electronic medical records (EMRs) directly from the clinics' systems, Sanguine integrates rich clinical information alongside each biospecimen, resulting in a comprehensive dataset that researchers can leverage. This process is complemented by a remote consent system that allows patients to join Sanguine's donor community without adding any operational strain to the clinics.

Gerald Lee, co-founder and Chief Product Officer at Sanguine Biosciences, remarked, “By leveraging our infrastructure, technology, and operations, Sanguine has partnered with over 20 oncology clinics across the United States. This empowers researchers with timely access to a diverse group of highest-quality patient samples.” The inclusion of treatment-naive biospecimens is particularly seen as a pivotal enhancement to studies focusing on biomarker discovery, drug development, and personalized cancer therapies.

Comprehensive Capabilities to Support Research

The expanded oncology capabilities at Sanguine Biosciences complement its existing robust network of donors, enhanced logistics solutions, and advanced data integration services. Researchers can now obtain:
1. Treatment-naive samples across various cancer types.
2. Longitudinal data through minimally invasive collections to monitor disease progression.
3. Matched blood products, which include plasma, serum, and PBMCs.
4. Detailed EMRs along with clinical and demographic metadata to provide deeper translational insights.

As cancer research continues to progress rapidly, the demand for clinically annotated biospecimens remains critical. Sanguine's initiative addresses this prominent challenge, enabling academic institutions, biotech entities, and pharmaceutical scientists to expedite their discoveries and bring new diagnostics and treatments to patients more efficiently.

For more detailed information about Sanguine's oncology biospecimen offerings or to request samples, please visit Sanguine Biosciences. By focusing on the marriage of annotated biospecimens with real-world data, Sanguine is setting the stage for advanced biomarker discovery and validation studies, bridging gaps between patients and the scientific community.

Furthermore, Sanguine Biosciences is an esteemed entity recognized as a “Great Place to Work” for four consecutive years, highlighting its commitment to fostering an engaging and supportive work environment. This also underscores its dedication to aiding the pursuit of personalized medicine by facilitating patient participation in vital biomedical research.